Cell therapy for hard-to-treat epilepsy starting in both temporal lobes
Part of Brain & nervous system clinical trials.
This trial tests a new cell therapy (NRTX-1001) for people with epilepsy that starts in both sides of the brain's temporal lobes and doesn't get better with medication. It aims to reduce or stop seizures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had at least 4 focal seizures per month for the last 6 months, and at least 2 of these seizures caused observable symptoms.
- Your seizures come from both the right and left hippocampus (part of the brain's temporal lobe), confirmed by EEG or brain scans.
- You have tried at least 2 anti-seizure medicines that didn't work well enough.
- Your current seizure medicines and doses have been stable for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a low-intensity focused ultrasound treatment aimed at reducing seizures caused by problems in one side of the hippocampus (a brain area involved in memory and seizures). It’s for people whose seizures have not responded to several seizure medicines and who have been offered a specific type of surgery.
This Phase 3 study tests a neural cell therapy (NRTX-1001) for adults whose seizures come from one side of the hippocampus and have not improved with standard seizure medicines. The goal is to reduce seizure frequency and improve seizure control where other treatments have not worked.
This early-stage trial tests whether transplanting special cells (UX-GIP001) into the brain can reduce seizures in people with drug-resistant epilepsy affecting the mesial temporal lobe—a common seizure origin that doesn't respond well to medications. The goal is to evaluate safety and whether this approach helps control seizures.
This trial tests a new cell therapy, UX-GIP001, for people whose seizures start in one small area of the brain (the mesial temporal lobe) and are not controlled by at least two seizure medications. The goal is to see if this treatment can safely reduce seizures.
This trial tests a type of brain stimulation therapy (TIS) for people with temporal lobe epilepsy that hasn't responded well to seizure medications. The goal is to help reduce how often seizures happen.
This trial tests a one-time gene therapy (AMT-260) for adults whose seizures start in one area of the brain (the temporal lobe) and aren't controlled by medication. The goal is to see if it's safe and reduces seizure frequency.
Hear when a new Epilepsy, Temporal Lobe trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.